Penpulimab
Penpulimab (AK105) · PD-1 immune checkpoint inhibitor
Fc-silent PD-1 blocker for nasopharyngeal carcinoma — class-typical, infrequent immune interstitial nephritis
PD-L1 immune checkpoint inhibitor
Cejemly · PD-L1 inhibitor
PD-L1 immune checkpoint inhibitor · approved 2021 · 5 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A full-length anti-PD-L1 antibody whose kidney is its immune system: rare but real autoimmune interstitial nephritis.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
No sugemalimab-specific renal-injury incidence has been published; the GEMSTONE registrational trials reported no nephritis among the most common grade 3-4 treatment-related adverse events (which were dominated by myelosuppression and immune-mediated pneumonitis). By extrapolation from the PD-1/PD-L1 checkpoint-inhibitor class, immune-related AKI occurs in roughly 2-5% of treated patients (higher with combination checkpoint blockade), with clinically significant/biopsy-confirmed acute interstitial nephritis being the dominant lesion. A separate real-world cohort of 1,037 ICI-treated patients supplies the drug-attributable denominator this class otherwise lacks: 18.2% developed AKI of any cause, but only 3.6% (37 patients) had AKI attributed to the checkpoint inhibitor itself — a class figure, not a sugemalimab-specific one.Source: Drug-attributable ICI-AKI rate (3.6%) from Lumlertgul et al., Eur J Cancer 2023 (PMID 37499561); class incidence and lesion distribution from Cortazar et al., J Am Soc Nephrol 2020 (PMID 31896554) and the ASON position statement, Kidney Int 2024 (PMID 39455026); sugemalimab trial safety from GEMSTONE-302 (PMID 35038432) and GEMSTONE-301 (PMID 35038429), in which renal events were not among the prominent toxicities.
Median ~14 weeks (IQR 6–37) from ICI start to AKI — later than most drug-induced AIN.
Distilled from: “Delayed — typically weeks to months after initiation; in the multicenter ICI-AKI cohort median time from checkpoint-inhibitor start to AKI was about 14 weeks (IQR 6-37), later than most other drug-induced AIN.” · PMID 31896554 (opens PubMed in a new tab)
In the multicenter ICI-AKI cohort ~22% were rechallenged and ~23% of those developed recurrent AKI — feasible but an individualized, co-managed decision. PMID 31896554 (opens PubMed in a new tab)
Class-level checkpoint-inhibitor AKI recovery: in a 138-patient multicenter ICI-AKI cohort, complete, partial, and no recovery of kidney function occurred in roughly 40%, 45%, and 15% of patients respectively. Two covariates carried a better renal prognosis — treatment with steroids, and the PRESENCE of a concomitant tubulointerstitial-nephritis-causing medication (69% of patients were on one). The second is an observational association, not an intervention: the cohort analysed no effect of stopping that drug, and the likeliest reading is that a competing culprit makes the ICI a less certain cause. Rechallenge is feasible in selected patients but recurrent AKI occurs in about a quarter.PMID 31896554 (opens PubMed in a new tab)
Distilled from the agent's cited literature — educational, not a substitute for the primary sources.
Recovery across agentsThis agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Acute tubulointerstitial nephritis is the signature ICI renal lesion — dominant in 93% of the 60 biopsied patients in a 138-patient multicenter ICI-AKI cohort (a biopsy-lesion proportion, not a treated-population incidence). PMID 31896554 (opens PubMed in a new tab)
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Minority histologic pattern — tubulointerstitial nephritis dominates 93% of ICI-AKI biopsies, with ATN and other lesions making up the remainder. PMID 31896554 (opens PubMed in a new tab)
Case-level; glomerular lesions (2 membranous nephropathy, 2 minimal change disease) among 12 biopsy/nephrologist-attributed ICI nephrotoxicity cases. PMID 32601079 (opens PubMed in a new tab)
Tap a signature to trace where it strikes the nephron.
Representative incidence
Acute Interstitial Nephritis strikes: Interstitium.
Acute Interstitial Nephritis
Immune-mediated inflammation of the renal interstitium — the signature kidney injury of checkpoint inhibitors.
Sugemalimab is a fully human IgG4 monoclonal antibody that binds programmed death-ligand 1 (PD-L1) on tumor cells and antigen-presenting cells, blocking its engagement of PD-1 (and CD80) on T cells. This releases the inhibitory brake on tumor-reactive cytotoxic T lymphocytes, restoring antitumor immunity. It was developed and validated in the GEMSTONE-301 (stage III unresectable NSCLC consolidation) and GEMSTONE-302 (first-line metastatic NSCLC) phase 3 trials.
27 grade-indexed syndromes across 11 organ systems, written for checkpoint blockade as a class rather than per agent — where a rate differs between anti-PD-1, anti-PD-L1, anti-CTLA-4 and combination therapy, the card names the class it was measured in.
Class-level context for the major non-renal toxicities of the PD-L1 immune checkpoint inhibitor class.
Endocrine
Thyroiditis, hypophysitis, diabetes
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
Pulmonary
Pneumonitis, ILD, effusions, hypertension
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
5 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Everything below is FAERS — adverse events someone chose to report, about 23 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
23 total FAERS reports is below the 50 this atlas requires before quoting an odds ratio, so report counts are shown instead of RORs and none of these counts as a signal. A phenotype missing below was queried and never cleared even the nominal CI bar, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
23 reports is below the 50 this atlas requires before quoting a percentage, so the counts are shown instead of shares.
Reported with a death outcome
too few reports to express as a share
Reported with hospitalization
too few reports to express as a share
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Sugemalimab sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Penpulimab (AK105) · PD-1 immune checkpoint inhibitor
Fc-silent PD-1 blocker for nasopharyngeal carcinoma — class-typical, infrequent immune interstitial nephritis
Loqtorzi · PD-1 immune checkpoint inhibitor
First FDA-approved drug for nasopharyngeal carcinoma; renal risk is class-typical immune-mediated interstitial nephritis.
Unloxcyt · PD-L1 immune checkpoint inhibitor
PD-L1 blockade for cutaneous SCC — watch for late immune interstitial nephritis
Opdivo · PD-1 checkpoint inhibitor
PD-1 inhibitor; ICI acute interstitial nephritis is the prototype.
Immune checkpoint inhibitor
Acute interstitial nephritis with long latency.
Keytruda · PD-1 checkpoint inhibitor
PD-1 inhibitor; ICI interstitial nephritis, varied glomerular lesions.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.